{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"151","upperLimit":"156","value":"153"},{"groupId":"OG001","lowerLimit":"206","upperLimit":"223","value":"215"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Cmax was obtained directly from the concentration versus time curve. Single dose PK data on Day 1 were summarized by dose level, such that all 10 mg arms were combined as descriptive statistics of PK were only calculated for N greater than (\\>) 2 in which a measurement of greater than (\\>) lower limit of quantification (LLOQ) represents a valid measurement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received M3258 at a dose of 10 mg orally, QD or twice per week until disease progression.","id":"OG000","title":"M3258 10 mg QD or Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 20 mg Twice Per Week"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis set included all participants, who received at least one dose of study intervention, have no clinically important protocol deviations or important events affecting PK, and provide at least one measurable post-dose concentration. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: Pre-dose 1, 2, 3, 4, 5, 6, 8 and 24 hours post-dose (each Cycle is of 28 days)","title":"Part A: Single Dose: Maximum Observed Plasma Concentration (Cmax) of M3258","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}